Enfortumab vedotin - Astellas Pharma/Seagen
Alternative Names: AGS-22C3; AGS-22CE; AGS-22M6E; AGS-22ME; AGS-M6; ASG-22CE; ASG-22M6E; ASG-22ME; Enfortumab; Enfortumab vedotin-ejfv; PADCEVLatest Information Update: 29 Aug 2024
At a glance
- Originator Agensys; Seattle Genetics
- Developer Astellas Pharma; Astellas Pharma Global Development; Merck & Co; Seagen; Utah State University
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Urogenital cancer
- Phase III Bladder cancer
- Phase II Prostate cancer; Solid tumours
Most Recent Events
- 28 Aug 2024 Launched for Urogenital cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Sweden (IV)
- 28 Aug 2024 Registered for Urogenital cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Liechtenstein, Norway, Iceland (IV)
- 28 Aug 2024 Registered for Urogenital cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in European Union (IV)